Dana-Farber Cancer Institute v. Ono Pharmaceutical Co., Ltd.

  1. October 16, 2020

    Full Fed. Circ. Won't Review Inventorship Row Over Cancer IP

    The full Federal Circuit Friday rejected a bid from Bristol-Meyers and others for review of a panel decision that two American scientists from the Dana-Farber Cancer Institute should be named as co-inventors on six patents involved in Nobel Prize-winning cancer research.

  2. September 15, 2020

    Dana-Farber Tells Fed. Circ. Not To Revisit Inventorship Ruling

    The Dana-Farber Cancer Institute is urging the full Federal Circuit not to reconsider a panel decision requiring a pair of American scientists to be named as co-inventors on patents involved in Nobel Prize-winning cancer research.

  3. July 14, 2020

    Fed. Circ. Upholds Dana-Farber's IP Inventorship Victory

    The Federal Circuit on Tuesday affirmed that a pair of American scientists should be named as co-inventors on six patents involved in Nobel Prize-winning cancer research, finding Ono Pharmaceutical was trying to push "an unnecessarily heightened inventorship standard."

  4. July 09, 2020

    Patent Cases To Watch In The Second Half Of 2020

    A wave of U.S. Supreme Court petition denials has made 2020 a bit of a letdown for patent attorneys, but there are several high-profile cases on the horizon that could decide the fate of Patent Trial and Appeal Board judges and biosimilars law, and offer more clarity on licensing standard essential patents.

  5. May 08, 2020

    Fed. Circ. Weighs Scientists' Ties To Cancer Patents

    A Federal Circuit panel grappled Friday with where to draw the line between collaboration and significant contributions in determining whether a district court wrongly ordered two scientists to be named as co-inventors on six patents involved in Nobel Prize-winning cancer research.